20%2. Despite the dismal prognosis, this tumour is particularly responsive to both radiation and cytotoxic chemotherapy, and effective palliation can be obtained with these treatments.
CASE HISTORY
A man aged 52 years presented in 1985 with urinary symptoms and an enlarged irregular prostate. A transurethral resection of the prostate (TURP) revealed well differentiated adenocarcinoma. Serum acid phosphatase was normal, and investigations showed stage T3c Nl MO disease. The patient was treated with radical radiotherapy to the pelvic lymph nodes (44 Gy in 22 fractions) and prostate (64 Gy in 32 fractions). The urinary symptoms resolved and the prostate returned to normal size.
In 1988 a symptomatic sacral bone metastasis developed; acid phosphatase and prostate specific antigen were normal. Bilateral orchidectomy gave good pain relief. 7 years after initial diagnosis, in 1992, right arm weakness developed. Computed tomographic (CT) scanning of the brain showed multiple metastases (Figure 1 ).
Brain metastases are rare in prostate cancer3, and a second primary tumour was not clinically apparent. Brain biopsy was not performed, and he was treated with whole brain radiotherapy (45 Gy in 20 fractions) under steroid cover. The symptoms resolved and a CT scan performed nine (b) Figure 1 (a) Multiple brain metastases from small-cell carcinoma of the prostate and (b) resolution 2 months later after whole-brain radiotherapy weeks later showed complete resolution of the brain metastases ( Figure 1 ). 2 months later the patient returned with weight loss, back pain and recurrence of urinary symptoms. The prostate was enlarged and material from a repeat TURP showed small-cell carcinoma within residual adenocarcinoma. Neuroendocrine differentiation was shown immunocytochemically with a chromogranin stain. Restaging investigations showed metastases in the liver (Figure 2 ), para-aortic lymph nodes and the axial skeleton.
The patient was treated with intravenous doxorubicin 40 mg/m2 and cyclophosphamide 600 mg/m2 on day 1, and etoposide 100 mg/m2 on days 1-3. This was given every 21 days to a total of six cycles. Clinically he responded well, with resolution of back pain and reduction in urinary symptoms. A CT scan after chemotherapy showed complete resolution of liver metastases (Figure 2) painful lumbar spine metastases, and after 9 months there was evidence of renewed metastatic growth in the brain and widespread nodal disease. This was refractory to further treatment and the patient died a month later. COMMENT The diagnosis of SCCP should be suspected when the pattern of metastatic spread is unusual for a prostatic adenocarcinoma. Up to half the cases present with an endocrine syndrome due to ectopic hormone secretion. Cushing's syndrome, hypercalcaemia and the syndrome of inappropriate antidiuretic hormone secretion have all been described1 4. Pathological diagnosis should be sought, based on characteristic morphology and immunocytochemical evidence of neuroendocrine differentiation. Prostate specific antigen is not expressed in the serum or in histopathological sections of patients with SCCP1. Two short retrospective series on treatment of SCCP have been published2'5. Two-thirds of patients responded to chemotherapy, with combinations of doxorubicin, cyclophosphamide, cisplatin, etoposide and vincristine in regimens similar to those used against small-cell lung cancer. The mean duration of response was 9.4 months5. SCCP does not respond to antiandrogen therapy. Responsiveness to radiotherapy has been reported previously and our patient did strikingly well, as shown by the resolution of the brain metastases on CT.
The dramatic responses to radiotherapy and chemotherapy underline the importance of diagnosing this form of prostatic cancer, where good palliation can be obtained.
